Ann C Childress

Summary

Publications

  1. ncbi request reprint Attention-deficit/hyperactivity disorder with inadequate response to stimulants: approaches to management
    Ann C Childress
    Center for Psychiatry and Behavioral Medicine, Inc, 7351 Prairie Falcon Road, Suite 160, Las Vegas, NV, 89128, USA
    CNS Drugs 28:121-9. 2014
  2. doi request reprint Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder
    Ann C Childress
    Center for Psychiatry and Behavioral Medicine, 7351 Prairie Falcon Road, Suite 160, Las Vegas, NV 89128, USA
    Adv Ther 29:385-400. 2012
  3. doi request reprint Pharmacotherapy of attention-deficit hyperactivity disorder in adolescents
    Ann C Childress
    Center for Psychiatry and Behavioral Medicine, Inc, Las Vegas, NV 89128, USA
    Drugs 72:309-25. 2012
  4. doi request reprint Efficacy and safety of dexmethylphenidate extended-release capsules administered once daily to children with attention-deficit/hyperactivity disorder
    Ann C Childress
    Center for Psychiatry and Behavioral Medicine Inc, Las Vegas, Nevada 89128, USA
    J Child Adolesc Psychopharmacol 19:351-61. 2009
  5. doi request reprint The use of lisdexamfetamine dimesylate for the treatment of ADHD
    Ann C Childress
    Center for Psychiatry and Behavioral Medicine, Inc, 7351 Prairie Falcon Road, Suite 160, Las Vegas, NV, USA
    Expert Rev Neurother 12:13-26. 2012
  6. pmc Efficacy and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: sex and age effects and effect size across the day
    Sharon B Wigal
    University of California, Irvine, Child Development Center, Irvine, California, USA
    Child Adolesc Psychiatry Ment Health 4:32. 2010
  7. ncbi request reprint The effects of lisdexamfetamine dimesylate on emotional lability in children 6 to 12 years of age with ADHD in a double-blind placebo-controlled trial
    Ann C Childress
    1Center for Psychiatry and Behavioral Medicine, Las Vegas, NV, USA
    J Atten Disord 18:123-32. 2014
  8. doi request reprint The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension
    Ann C Childress
    Center for Psychiatry and Behavioral Medicine, Inc Las Vegas, NV, USA
    Postgrad Med 122:35-41. 2010
  9. doi request reprint Single-dose pharmacokinetics of NWP06, an extended-release methylphenidate suspension, in children and adolescents with ADHD
    Ann C Childress
    Center for Psychiatry and Behavioral Medicine, Inc, Las Vegas, NV, USA
    Postgrad Med 123:80-8. 2011

Collaborators

Detail Information

Publications9

  1. ncbi request reprint Attention-deficit/hyperactivity disorder with inadequate response to stimulants: approaches to management
    Ann C Childress
    Center for Psychiatry and Behavioral Medicine, Inc, 7351 Prairie Falcon Road, Suite 160, Las Vegas, NV, 89128, USA
    CNS Drugs 28:121-9. 2014
    ..For patients who are partial responders to stimulants, despite adequate adherence and dose optimization, the addition of atomoxetine or guanfacine extended release or clonidine extended release may help them achieve adequate response. ..
  2. doi request reprint Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder
    Ann C Childress
    Center for Psychiatry and Behavioral Medicine, 7351 Prairie Falcon Road, Suite 160, Las Vegas, NV 89128, USA
    Adv Ther 29:385-400. 2012
    ..Additional studies should further explore the role of adjunctive GXR in clinical practice to help identify those patients most likely to benefit from such therapy...
  3. doi request reprint Pharmacotherapy of attention-deficit hyperactivity disorder in adolescents
    Ann C Childress
    Center for Psychiatry and Behavioral Medicine, Inc, Las Vegas, NV 89128, USA
    Drugs 72:309-25. 2012
    ..Therefore, clinical decisions used in selecting pharmacotherapy to treat ADHD in children aged 6-12 years can be applied in the adolescent population...
  4. doi request reprint Efficacy and safety of dexmethylphenidate extended-release capsules administered once daily to children with attention-deficit/hyperactivity disorder
    Ann C Childress
    Center for Psychiatry and Behavioral Medicine Inc, Las Vegas, Nevada 89128, USA
    J Child Adolesc Psychopharmacol 19:351-61. 2009
    ..d.]) dexmethylphenidate hydrochloride (HCl) extended-release (d-MPH XR; Focalin XR) across multiple settings to treat pediatric attention-deficit/hyperactivity disorder (ADHD)...
  5. doi request reprint The use of lisdexamfetamine dimesylate for the treatment of ADHD
    Ann C Childress
    Center for Psychiatry and Behavioral Medicine, Inc, 7351 Prairie Falcon Road, Suite 160, Las Vegas, NV, USA
    Expert Rev Neurother 12:13-26. 2012
    ..However, LDX is still classified as a controlled substance. In this article, the pharmacokinetic parameters and efficacy and safety of LDX are reviewed...
  6. pmc Efficacy and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: sex and age effects and effect size across the day
    Sharon B Wigal
    University of California, Irvine, Child Development Center, Irvine, California, USA
    Child Adolesc Psychiatry Ment Health 4:32. 2010
    ..abstract:..
  7. ncbi request reprint The effects of lisdexamfetamine dimesylate on emotional lability in children 6 to 12 years of age with ADHD in a double-blind placebo-controlled trial
    Ann C Childress
    1Center for Psychiatry and Behavioral Medicine, Las Vegas, NV, USA
    J Atten Disord 18:123-32. 2014
    ..To evaluate the effect of lisdexamfetamine dimesylate (LDX) on emotional lability (EL) in children with ADHD...
  8. doi request reprint The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension
    Ann C Childress
    Center for Psychiatry and Behavioral Medicine, Inc Las Vegas, NV, USA
    Postgrad Med 122:35-41. 2010
    ..To determine the single-dose pharmacokinetics of 60 mg NWP06, a novel extended-release (ER) liquid formulation of methylphenidate (MPH) compared with 30 mg immediate-release (IR) liquid MPH, dosed at Hours 0 and 6, in adults...
  9. doi request reprint Single-dose pharmacokinetics of NWP06, an extended-release methylphenidate suspension, in children and adolescents with ADHD
    Ann C Childress
    Center for Psychiatry and Behavioral Medicine, Inc, Las Vegas, NV, USA
    Postgrad Med 123:80-8. 2011
    ..As such, there is a medical need for a liquid extended-release preparation of methylphenidate for the management of ADHD in children who are unable or unwilling to swallow solid formulations...